Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.13 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | 3.59 | 3.93 | 3.91 | 12.27 | 6.46 | 6.62 | 45.99 | 22.18 | 2.07 | 12.66 | 10.24 |
| — | — | -44.5% | -40.7% | -91.5% | -44.7% | +212.5% | -47.7% | +349.2% | -12.3% | -87.0% | +90.3% | -73.5% | |
| P/B Ratio | 0.87 | 0.62 | 1.04 | 0.58 | 0.58 | 1.18 | 1.64 | 1.29 | 2.16 | 1.18 | 0.42 | 0.58 | 0.59 |
| — | -47.6% | -36.2% | -54.7% | -73.2% | +0.1% | +286.0% | +122.9% | +269.0% | +17.7% | -68.6% | -46.0% | -81.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 0.40 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
C4 Therapeutics, Inc.'s operating margin was 92.8% in Q4 2025, up 399.3 pp QoQ and up 821.2 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -264.4% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 51.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 65.9% | 86.6% | 83.0% | 100.0% | 48.1% | 82.0% | 100.0% | -672.6% |
| — | +51.8% | +15.5% | +20.5% | 0.0% | +36.9% | +5.7% | -17.0% | +114.9% | +104.9% | +124.2% | +179.1% | -177.5% | |
| Operating Margin | — | 92.8% | -306.4% | -441.0% | -402.9% | -728.4% | -183.9% | -178.6% | -1060.2% | -1147.7% | -251.2% | -1410.2% | -963.8% |
| — | +112.7% | -66.7% | -146.9% | +62.0% | +36.5% | +26.8% | +87.3% | -10.0% | +14.5% | +47.8% | -612.4% | -135.2% | |
| Net Margin | — | 82.2% | -286.4% | -402.6% | -363.7% | -667.8% | -160.6% | -147.6% | -933.2% | -1065.7% | -244.2% | -1348.4% | -925.2% |
| — | +112.3% | -78.4% | -172.8% | +61.0% | +37.3% | +34.2% | +89.1% | -0.9% | +18.2% | +48.4% | -580.5% | -124.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.4% | -10.0% | -19.6% | -14.1% | -12.8% | -15.1% | -10.1% | -7.0% | -11.2% | -15.0% | -12.0% | -14.5% | -12.6% |
| — | +33.9% | -94.4% | -101.0% | -13.9% | -0.2% | +16.2% | +51.6% | +10.8% | -22.8% | -24.7% | -87.3% | -50.4% | |
| ROA | -29.6% | -6.6% | -11.4% | -8.4% | -7.9% | -9.5% | -6.5% | -4.5% | -7.3% | -9.8% | -7.6% | -9.3% | -8.4% |
| — | +31.2% | -75.7% | -85.8% | -7.5% | +2.7% | +14.7% | +51.2% | +13.0% | -17.5% | -14.0% | -71.3% | -36.0% | |
| ROIC | -36.9% | -8.7% | -16.3% | -11.6% | -10.1% | -11.9% | -8.6% | -6.7% | -11.3% | -13.4% | -8.3% | -9.9% | -8.4% |
| — | +26.7% | -89.9% | -74.1% | +10.7% | +11.6% | -3.1% | +32.2% | -33.8% | -64.6% | -25.1% | -87.3% | -36.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 36.9% YoY to 7.81x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 0.40 | 0.36 | 0.33 | 0.30 | 0.28 | 0.28 | 0.27 | 0.29 | 0.33 | 0.36 | 0.33 |
| — | -23.2% | +44.0% | +30.5% | +22.2% | +5.6% | -17.2% | -22.7% | -17.1% | -4.3% | +20.7% | +43.0% | +35.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.81 | 7.81 | 5.76 | 5.06 | 5.70 | 5.71 | 6.31 | 5.09 | 5.08 | 6.34 | 7.39 | 5.69 | 7.07 |
| — | +36.9% | -8.8% | -0.7% | +12.1% | -10.0% | -14.6% | -10.5% | -28.1% | -1.8% | +2.8% | -17.5% | +9.7% | |
| Quick Ratio | 7.81 | 7.81 | 5.76 | 5.06 | 5.70 | 5.71 | 6.31 | 5.09 | 5.08 | 6.34 | 7.39 | 5.69 | 7.07 |
| — | +36.9% | -8.8% | -0.7% | +12.1% | -10.0% | -14.6% | -10.5% | -28.1% | -1.8% | +2.8% | -17.5% | +9.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -166.51 | -62.61 | -59.78 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonC4 Therapeutics, Inc.'s current P/E is -2.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking C4 Therapeutics, Inc.'s business trajectory between earnings reports.